The IL-12/IL-23 blocker ustekinumab was effective in a patient with BP and psoriasis [85], but paradoxical reactions are possible, as suggested by cases of BP arising in psoriatic patients receiving ustekinumab [89]. Here, IL23A is linked to psoriasis.